samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > prion safety of biopharmaceuticals and blood-related products
PUBLICATIONS
European Biopharmaceutical Review

Prion Safety of Biopharmaceuticals and Blood-Related Products

Biopharmaceutical products such as recombinant proteins, monoclonal antibodies, vaccines, and blood- and plasma-related products, must fulfil complex requirements regarding quality and safety. Many of these products have often had contact with bovine material, either as a constituent of the product itself, or by indirect contact during production. Since bovine spongiform encephalopathy (BSE) was identified in the UK in 1986, the use of bovine material in medicinal products has prompted action by national and international regulatory authorities to assure the continued safety of these products.This article provides a brief overview of the subject of prion safety, the actions of international regulatory authorities, and the consequences for the manufacturing industry of medicinal products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Melanie Dippel, Corporate Communications Manager
at NewLab BioQuality AG in Germany Melanie Dippel is currently Corporate Communications Manager at NewLab BioQuality AG - a Germany-based company providing GLP-compliant quality control testing and analysis on all major types of biopharmaceuticals.
With more than four years' experience in public relations work for different biotech organisations, she joined NewLab BioQuality AG in February of this year. Melanie received her Diploma in Molecular Biology and Biochemistry from the University of Düsseldorf in Germany.

spacer
Melanie Dippel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

H&T Presspart announces partnership with BIOCORP for the InspairTM digital technology

H&T Presspart (a division of the German based Heitkamp & Thumann Group), announces today that a new partnership deal has been signed with BIOCORP, a French based company specialised in the development and manufacture of medical devices and connected healthcare solutions, whereby H&T Presspart is licensed to sell and promote BIOCORP’s InspairTM smart add-on device for metered-dose inhalers.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement